EyePoint, Inc. 8-K

What Happened
EyePoint, Inc. announced on July 17, 2026 that it entered a Settlement Agreement with the U.S. Department of Justice (DOJ), the Office of Inspector General of HHS (OIG‑HHS), the Defense Health Agency (DHA/TRICARE) and a relator to resolve alleged civil claims related to sales, marketing and sampling practices for DEXYCU® (commercialized 2019–2023). The Company agreed to pay $4,678,981.86 plus interest (4.25% per year from January 28, 2026) and $166,500 for the relator’s counsel fees. Payment is expected from cash on hand. In connection with the settlement, EyePoint entered a Corporate Integrity Agreement with OIG‑HHS dated July 13, 2026 that runs five years and imposes enhanced federal health‑care compliance obligations. The settlement avoids protracted litigation and does not constitute an admission of liability.

Key Details

• Settlement payment: $4,678,981.86 total; split as $4,657,463.18 (to the United States) and $21,518.68 (to participating states).
• Interest and timing: 4.25% interest per annum from Jan 28, 2026; Settlement Payment due no later than 14 days after the July 17, 2026 Effective Date.
• Relator counsel fees: $166,500 due no later than 60 days after the Effective Date. Company intends to use cash on hand.
• Corporate Integrity Agreement (dated July 13, 2026): five‑year term; requires a Compliance Officer, Compliance Committee, board oversight and expert, written policies, training, employee screening, independent reviews and risk assessments; OIG‑HHS agreed not to seek exclusion from federal health programs in exchange for compliance.

Why It Matters
This filing signals a near‑term cash outflow (~$4.68M plus $166.5K) to resolve government and relator claims tied to DEXYCU activity from 2019–2023 and removes litigation uncertainty. The Corporate Integrity Agreement creates ongoing compliance obligations and monitoring that may increase governance and compliance costs and requires continued attention by management and the board. OIG‑HHS’s agreement not to seek exclusion is important for company participation in federal health programs, but failure to meet the CIA terms could still lead to penalties or exclusion.